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Background: The aim of this study was to compare outcome of patients with previous cardiac surgery undergoing
transapical aortic valve implantation (Redo-TAVI) to those undergoing classic aortic valve replacement (Redo-AVR)
by using propensity analysis.
Methods: From January 2005 through May 2012, 52 high-risk patients underwent Redo-TAVI using a pericardial
xenograft fixed within a stainless steel, balloon-expandable stent (Edwards SAPIEN™). During the same period of
time 167 patients underwent classic Redo-AVR. Logistic regression analysis was used to identify covariates among
11 baseline patient variables including the type of initial surgery. Using the significant regression coefficients, each
patient’s propensity score was calculated, allowing selectively matched subgroups of 40 patients each. Initial surgery
included coronary artery bypass grafting in 30 patients, aortic valve replacement in 7 patients and mitral valve
reconstruction in 3 patients in each group. Follow-up was 4 ± 2 years and was 100% complete.
Results: Postoperative chest tube drainage (163 ± 214 vs. 562 ± 332 ml/24 h, p = 0.02) and incidence of early
permanent neurologic deficit (0 vs. 13%, p = 0.04) was lower in patients with Redo-TAVI and there was a trend
towards improved 30-day survival (p = 0.06). Also we detected a decreased ventilation time (p = 0.04) and lower
transfusion rate of allogenic blood products (p≤ 0.05) in the Redo-TAVI group. At late follow up differences regarding
incidence of major adverse events, including death and permanent neurologic deficits (25% vs. 43%, p = 0.01)
statistically supported early postoperative findings.
Conclusion: The encouraging results regarding early and long-term outcomes following TAVI in patients with previous
cardiac surgery show, that this evolving approach may be particularly beneficial in this patient cohort.
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High-risk patients with severe symptomatic degenerative
aortic stenosis (AS) who had previously undergone car-
diac operation represent a surgically challenging patient
cohort [1,2]. Mediastinal reentry during cardiac reopera-
tions especially in patients with previous coronary artery
bypass grafting (CABG) bears an elevated risk of myocar-
dial and graft injury and is associated with an increased
periprocedural morbidity and mortality [3]. Currently, sur-
gical aortic valve replacement (AVR) represents the gold
standard of treatment of degenerative AS with appropriate
long-term outcomes [3,4].
Transcatheter based aortic valve implantation (TAVI)
has been suggested as an alternative to classic surgery
especially in patients with severe comorbidities carrying
an unacceptably high perioperative risk and has been
demonstrated to be non-inferior to AVR in this patient
cohort [5-8]. Due to the minimally invasive nature of
this approach that eliminates the need of cardiopulmonary
bypass (CPB) and myocardial protection issues, TAVI may
be particularly helpful in elderly high risk redo patients.
The aim of this study was to compare outcome of
patients with previous cardiac surgery undergoing transapi-
cal aortic valve implantation (Redo-TAVI) to those under-
going classic aortic valve replacement (Redo-AVR) by
using propensity analysis.
Methods
Study design and patient population
This report represents a comparative retrospective single-
centre study. Patient data were prospectively collected
during treatment using standardized forms to record
demographic and clinical characteristics as well as proced-
ural and follow up data. Follow up was obtained postoper-
atively at 30 days, 6 months and annually based on the
medical records and on physician and patient interviews.
Since stroke represents a devastating complication follow-
ing cardiac surgery with a dramatic impairment of quality
of life we additionally analyzed the incidence of major
adverse events (stroke and death) at late follow-up using
Kaplan Meier analysis. All patients underwent transtho-
racic echocardiography at the time of discharge, at 6
moths, 12 months and yearly thereafter. Full data were ob-
tained in all patients. The mean follow-up was 4 ± 2 years.
The local Ethics Committee at the Hospital of the Johann
Wolfgang Goethe University, Frankfurt/Main, Germany
approved the study protocol and individual patient consent
was waived.
Between January 2005 and May 2012, 52 high risk
patients underwent Redo-TAVI and 167 Redo-AVR after
pervious cardiac surgery. All Redo-TAVI and Redo-AVR
procedures were performed at the Division of Thoracic
and Cardiovascular Surgery of Johann Wolfgang Goethe
University, Frankfurt Main, Germany. Using the significantregression coefficients, each patient’s propensity score was
calculated, allowing selectively matched subgroups of 40
patients each. Patient demographics and baseline data of
the matched subgroups are reported in Table 1. As a result
of our matching process preoperative comorbidities
and other important clinical variables were comparable
between the two groups. Prior to surgery, the mean trans-
valvular gradient was considerably increased (Redo-TAVI:
57 ± 21 mmHg vs. Redo-AVR: 51 ± 16 mmHg; p = 0.56)
and the aortic valve orifice area (Redo-TAVI: 0.63 ±
0.29 cm vs. Redo-AVR: 0.68 ± 0.31 cm; p = 0.65) severely
reduced in both groups.
Patient selection for TAVI in patients with previous
cardiac surgery (Redo-TAVI): inclusion criteria
High-risk patients who had previously undergone cardiac
operation with severe symptomatic aortic stenosis and an
aortic valve orifice area of 0.8 cm2 or less were selected for
the purpose of this study. The baseline operative risk was
estimated by the logistic EuroSCORE and the according
STS risk score [9-13]. High risk was defined by a logistic
EuroSCORE predicted risk for mortality greater than 20%
or a STS risk score greater than 10%. Additional inclusion
criteria were an age of 75 years or older and symmetrically
distributed calcification of the stenotic native aortic valve
cusps. The therapeutic option of Redo-TAVI was dis-
cussed extensively with all patients considered suitable for
inclusion in the study, focusing on the overall risk profile
of the individual patient, on the preoperative activities of
daily living, the motivation of the individual patient, and
on the ongoing results of the new technique. The choice
of treatment was made at the discretion of the heart team,
consisting of cardiac surgeons and interventional cardiolo-
gists. Preinterventional patient screening included trans-
thoracic and transesophageal echocardiography as well as
coronary artery angiography for exclusion of coronary
heart disease. Applying these guidelines, we treated 52 con-
secutive patients who had previously undergone cardiac
surgery between January 2005 and May 2012 with an aver-
age logistic EuroSCORE predicted risk for mortality
of 25 ± 5% and an according STS risk score of 11 ±
4%. Patient demographics of the propensity-matched
patients in the Redo-TAVI group are summarized in
Table 1.
Patient selection for Redo-TAVI: exclusion criteria
The presence of one or more of the following comor-
bidities was considered a contraindication for Redo-
TAVI. Echocardiographically evidenced bicuspid aortic
valve, noncalcified aortic stenosis, intracardiac thrombus,
endocarditis, ejection fraction less than 20%, hypertrophic
obstructive cardiomyopathy, untreated symptomatic cor-
onary artery disease, myocardial infarction within less than
1 month and recent stroke.
Table 1 Baseline characteristics of the propensity-matched patients of the Redo-TAVI and Redo-AVR group
All patients Propensity-matched patients
Redo-TAVI (n = 52) Redo-AVR (n = 167) Redo-TAVI (n = 40) Redo-AVR (n = 40)
Variables No. (%) No. (%) p value No. (%) No. (%) p value
Age (years) 82 ± 5 72 ± 9 0.07 81 ± 4 80 ± 3 >0.99
Log EuroSCORE|| 25 ± 5 17 ± 2 0.11 24 ± 6 19 ± 6 0.58
STS risk score 11 ± 4 9 ± 2 0.07 11.1 ± 2.8 10.4 ± 3 0.65
Male 31 (60) 92 (55) 0.44 29 (73) 29 (73) >0.99
Arterial hypertension 22 (42) 106 (63) 0.14 16 (40) 18 (45) 0.69
Pulmonary hypertension 16 (31) 72 (43) 0.24 5 (13) 5 (13) >0.99
Diabetes 20 (38) 43 (26) 0.42 17 (42) 14 (35) 0.54
CAD‡ 45 (87) 42 (25) 0.03 33 (83) 30 (75) 0.46
COPD§ 19 (36) 37 (22) 0.67 9 (23) 8 (20) 0.81
Chronic renal failure* 30 (58) 21 (12) 0.05 20 (50) 16 (40) 0.43
Peripheral vascular disease 23 (44) 24 (14) 0.04 13 (33) 11 (27) 0.43
Cerebrovascular disease 20 (38) 31 (18) 0.07 9 (23) 8 (20) 0.81
LV-EF < 30¶ 21 (40) 39 (23) 0.06 9 (23) 9 (23) >0.99
Mean ejection fraction 39 ± 18 44 ± 14 0.62 48 ± 14 47 ± 12 0.77
Aortic valve area (cm) 0.65 ± 0.24 0.5 ± 0.31 0.46 0.63 ± 0.29 0.68 ± 0.31 0.65
Mean pressure gradient (echo; mmHg) 59 ± 18 57 ± 14 0.59 57 ± 21 51 ± 16 0.56
Peak to peak gradient (invasive; mmHg) 67 ± 27 70 ± 35 0.55 69 ± 36 65 ± 34 0.58
Mean time interval between initialand
current cardiac procedure (years)
7 ± 4 11 ± 8 0.60 7 ± 5 8 ± 6 0.78
‡CAD = coronary artery disease; §COPD = chronic obstructive pulmonary disease; ||EuroSCORE = European system for cardiac risk evaluation; ¶LV-EF = left ventricular
ejection fraction.
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(Redo-AVR)
During the same period of time (January 2005 - May
2012) 167 consecutive patients with severe aortic sten-
osis and previous cardiac surgery underwent Redo-AVR.
Of these 167 patients the mean logistic EuroSCORE was
17 ± 2% and the according STS risk score was 9 ± 2%.
Demographics of propensity-matched patients in the
Redo-AVR group are summarized in Table 1.
Propensity score analysis
The nonrandomness of procedure assignment was ad-
dressed by propensity matching to provide a more reliable
assessment of outcomes based on procedure type. Logistic
regression analysis was used to identify covariates among
11 baseline patient variables that were imbalanced in the 2
groups of interest (SPSS 11.0 for Windows; SPSS Inc,
Chicago, Ill). Variables included age, sex, logistic European
System for Cardiac Operative Risk Evaluation (EuroSCORE),
STS risk score, preoperative left ventricular ejection fraction
(LV-EF), chronic obstructive pulmonary disease (COPD),
pulmonary hypertension, peripheral vascular disease,
cerebrovascular disease, renal dysfunction, type of previ-
ous cardiac surgery procedure. By using the significant
regression coefficients, a propensity score was calculatedfor each patient. The total population was ranked by pro-
pensity score, allowing selectively matched subgroups of
40 patients each. The short- and long-term outcomes of
the patients were blinded during the matching process.
Resulting matched patients were analyzed for differences
in selected early and late outcomes.
Procedure: Redo-TAVI
Our institutional protocol for transapical TAVI has been
previously described in details [14-16]. Briefly, all opera-
tions were performed in a specially equipped angiography
suite that fulfils the standards of a hybrid operating room.
A monoplane fluoroscopic angiography system (Axiom
Sensis; Siemens, Munich, Germany) was used. Besides
standard hemodynamic monitoring, transesophageal echo-
cardiography and CPB were routinely available. A limited
left anterolateral incision (5–7 cm), in the fifth intercostal
space, was used to access the apex of the heart. A bipolar
epicardial pacing wire was placed and tested. Two U
stitches with Teflon felt pledgets using 3–0 Prolene poly-
propylene (Ethicon, Inc, Somerville, NJ) were placed in the
apex of the left ventricle. They served as a purse string for
linear closure of the left ventricle at the end of the proced-
ure. Following balloon valvuloplasty all valve deployments
were performed with standard volumetric inflation of the
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to guide the catheter across the native valve and direct de-
ployment of the stent at the level of the annulus. During
deployment, the heart was unloaded with rapid ventricular
pacing. Valve function was immediately assessed by angio-
graphic and echocardiographic visualization. Intercostal
blockade was performed with ropivacaine. The pericar-
dium was partially closed over the apex and a left lateral
chest tube inserted. The incision was closed in a standard
fashion.
Procedure: Redo-AVR
Our routine institutional protocol for patients with pre-
vious cardiac surgery includes dissection of the right
axillary artery and placement of a guide wire in the right
common femoral vein, prior to repeat sternotomy. Medi-
astinal structures were dissected and bypass grafts if
present identified. After systemic heparinization the axil-
lary artery was cannulated in the majority of Redo-AVR
patients (n = 36/40, 90%). Venous cannulation was per-
formed through the right atrial appendage. Cardio-
pulmonary bypass was initiated at moderate systemic
hypothermia (32°C). Cardiac arrest was achieved by in-
stillation of cardioplegic solution into the aortic root
and/or retrograde through a cardioplegic catheter placed
in the coronary sinus. If present, the patent left internal
thoracic artery bypass graft was dissected and occluded
during cross clamp time. A left ventricular vent was
placed most commonly through the superior right pul-
monary vein.
The stenotic native aortic valve or degenerated aortic
prosthesis was excised and aortic valve replaced in a stand-
ard fashion. A biologic prosthesis was used in all patients
with a mean size of 24 ± 2 mm (range, 19 to 27 mm).
Data analysis
Data are presented as frequency distributions and percent-
ages. All continuous data are expressed as means ± stand-
ard deviation. Categoric data are expressed as counts and
proportions. Comparisons were done with paired, 2-tailed
t test for means of normally distributed continuous vari-
ables and the Wilcoxon rank sum test for skewed data.
Fisher exact or χ2 test was used to analyze differences
among categoric data. For long-term survival, Kaplan-
Meier estimates were calculated and compared using the
log-rang test. Statistical analysis of data was conducted




In both groups, all cases were performed as elective pro-
cedures. Duration of procedure was significantly lower
in the Redo-TAVI group (106 ± 53 vs. 332.5 ± 120 min;p = 0.01). One patient (3%) in the Redo-TAVI group re-
quired temporary CPB support because of hemodynamic
instability after completion of Redo-TAVI procedure.
Two further patients (5%) in the Redo-TAVI group
received percutaneous coronary angioplasty. Table 2 sum-
marizes procedural characteristics of both groups.
Post-operative course and early outcomes
The clinical course of both groups is detailed in Table 3.
Postoperative chest tube drainage was significantly lower
in the Redo-TAVI group at 24 hours (mean 163 ± 214 vs.
mean 562 ± 332 ml/24 h; p = 0.02). We detected a de-
creased need of transfusion rate of allogenic blood prod-
ucts, including packed red blood cell concentrates (1 ± 1 U
vs. 6 ± 6 U; p = 0.04), fresh-frozen plasma (1 ± 1 U vs. 4 ± 3
U; p = 0.05) and platelet concentrates (0 U vs. 4 ± 1 U;
p = 0.01) in the Redo-TAVI group. Accordingly the
need of reexploration for bleeding was decreased in
the Redo-TAVI group (3% vs. 17%; p = 0.05). In patients
with Redo-TAVI, ventilation time (p = 0.04) and intensive
care unit stay (p = 0.03) were lower as compared to the
Redo-AVR group. Implantation of a permanent pace-
maker due to atrioventricular block was not necessary in
the Redo TAVI group. In contrast 3 patients required
permanent pacemaker implantation following Redo-AVR
(8%; p = 0.31).
Permanent neurologic deficits including stroke and
intracranial bleeding were detected with an incidence of
13% (n = 5) in the Redo-AVR group while no such major
neurologic events occurred in the Redo-TAVI group
(p = 0.04). There was a trend towards a decreased 30 day
mortality following Redo-TAVI (p = 0.06). The incidence
of major adverse events including death and permanent
neurologic complications within 30 days postoperatively
reached statistical significance between the two groups
and is depicted in Figure 1.
Late follow up
During late follow up 7 patients in the Redo-TAVI group
and 5 patients (p > 0.99) in the Redo-AVR group died.
The causes of late death in the transapical group were
sepsis (n: 3), cancer (n: 3) and unknown (n: 1). In the
surgical group 2 patients died for unknown reasons 13
and 31 months postoperatively. Two further patients of
Redo-AVR group died due to pneumonia and consequent
respiratory failure and one patient died due to pulmonary
malignoma. Actuarial survival rates for all patients are
illustrated in Figure 2. Kaplan Meier survival estimates at
4 years were 73 ± 4% for Redo-AVR patients and 75 ± 3%
(p = 0.56) for the Redo-TAVI group.
While 1 patient (3%) from Redo-AVR suffered a
permanent neurologic complication during the follow-up
time, late stroke was absent in the Redo-TAVI group
(p > 0.99). Overall none of the patients in the Redo-TAVI
Table 2 Procedural characteristics of the propensity-matched patients of the Redo-TAVI and Redo-AVR group
Propensity-matched patients
Redo-TAVI (n = 40) Redo-AVR (n = 40) p value
No. % No. %
Priority of procedure
Elective 40 100 40 100 >0.99
Duration of surgery/intervention (min) 106 ± 53 332.5 ± 120 0.01
CPB time* 171 ± 77
Cross clamp time 98 ± 42
Device Redo-TAVI
Edwards SAPIEN 23 mm 26 65
Edwards SAPIEN 26 mm 14 35
Valve type Redo-AVR
Carpentier Edwards Porcine Valve
19 mm 1 3
21 mm 7 17
23 mm 9 23
25 mm 19 47
27 mm 4 10
Immediate result
Successful valve/device implantation 40 100 40 100 >0.99
CBP support 1 3 40 100 >0.001
Additional procedures
PCI† 2 5 0 0 0.18
*CPB = Cardiopulmonary Bypass; †PCI = Percutaneous coronary intervention; TAVI = Transapical aortic valve implantation.
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ation (Figure 2). Kaplan Meier analysis of major adverse
events showed a significantly lower incidence at 4 year fol-
low up for the transcatheter group (n: 10, 25%) compared
to the surgical group (n: 17, 43%; p = 0.01).
A summary of echocardiographic results at late follow
up can be found in Table 4. Briefly, late echocardio-
graphic follow-up data revealed good valve function with
low transvalvular gradients in both groups. Ventricular
function was stable in both groups. Major difference
between the two groups was the presence of mild to
moderate paravalvular leakage in 33% of Redo-TAVI
patients, while this finding was absent in the Redo-AVR
group (p = 0.001). Interestingly, none of the 7 Redo-TAVI
patients who underwent a valve in a valve procedure
revealed paravalvular leakage in echocardiographic follow-
up. During follow-up there were no cases of endocarditis
or structural valve degeneration in either group.
Discussion
There is no doubt that cardiac surgery is facing the
challenge of increasing patient age and comorbidities, both
of which lead to a higher perioperative risk profile [17].
Transcatheter based aortic valve implantation is evolvingrapidly and provides a reliable and attractive alternative to
the established gold standard of classic AVR in patients
with severe comorbidities carrying an unacceptably high
perioperative risk [5]. The aim of the current study was to
compare outcome of patients with previous cardiac sur-
gery undergoing transapical aortic valve implantation
(Redo-TAVI) to those undergoing classic aortic valve re-
placement (Redo-AVR) by using propensity analysis.
The analysis of postoperative data regarding mortal-
ity revealed differences inherent in the two treatment
options. Regarding early operative outcomes, there was a
trend towards a higher 30 day mortality following Redo-
AVR as compared to Redo-TAVI patients (p = 0.06). Chal-
lenging technical issues during redo surgery increase the
surgical trauma which may lead to a complicated postop-
erative course and reported 30 day mortality following
Redo-AVR to be as high as 20% depending on the pre-
operative risk profile of the investigated patient cohort
[5,7,18-20]. Vohra et al. reported a 30 day mortality of 8%
in 104 patients undergoing Redo-AVR [1]. Similar results
were observed by Dobrilovic and colleagues, with a repor-
ted mortality of 6% in a series of 132 patients undergoing
Redo-AVR [21]. On the other hand the results of a sub-
group analysis in the PARTNER trial revealed an early
Table 3 The detailed clinical postoperative course of the propensity-matched patients of the Redo-TAVI and Redo-AVR
group
All patients Propensity-matched patients
Redo-TAVI (n = 52) Redo-AVR (n = 167) p value Redo-TAVI (n = 40) Redo-AVR (n = 40) p value
Variables No. (%) No. (%) No. (%) No. (%)
Ventilation time (h) 8 ± 6 18 ± 24 0.07 9 ± 7 31 ± 41 0.04
ICU stay (h)† 25 ± 21 65 ± 68 0.04 23 ± 20 74 ± 97 0.03
Postoperative complications
Bleeding complications
Postop. chest tube drainage (ml/24 h)§ 144 ± 209 580 ± 420 0.05 163 ± 214 562 ± 332 0.02
Surgical reexploration 2 (4) 13 (8) 0.09 1 (3) 7 (17) 0.05
Transfusion rate of allogenic
Blood products
PRBC (U)|| 1 ± 1 6 ± 6 0.03 1 ± 1 6 ± 6 0.04
FFP (U)* 1 ± 1 5 ± 5 0.04 1 ± 1 4 ± 3 0.05
PC (U)‡ 0 4 ± 2 0.01 0 4 ± 1 0.01
Low cardiac output 2 (4) 4 (2) 0.23 2 (5) 2 (5) >0.99
Acute kidney injury
Creatinin increase >300% 3 (5) 6 (4) 0.18 1 (3) 2 (5) 0.09
Permanent PM implantation^ 1 (2) 5 (3) 0.21 0 3 (8) 0.31
Cerebrovascular
TIA¶ 2 (4) 4 (2) 0.23 1 (3) 2 (5) 0.09
Major stroke (Rankin score >2) 0 7 (4) 0.07 0 5 (13) 0.04
Wound healing disorder
Conservative treatment 0 11 (7) 0.04 0 2 (5) 0.06
Surgical treatment 0 6 (4) 0.05 0 1 (3) 0.07
Thirty day mortality 3 (6) 14 (8) 0.14 3 (8) 6 (16) 0.06
*FFP = fresh-frozen plasma; †ICU = intensive care unit; ‡PC = Platelet cells; §Postop. = Postoperative; ||PRBC = packed red blood cells; ^PM= pace maker; ¶TIA = Transient
ischemic attack.
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previous CABG [5]. Although experienced surgeons
would find early mortality following Redo-AVR of 16% too
high, our observed 30 day mortality within the Redo-AVR
group seems to be in line with data reported in previous
series [1,5,7,18-21]. For the Redo-TAVI group our results
with respect to 30 day mortality can be considered good
as compared to the literature. D’Onofrio and colleagues
reported in a recent publication about a 30 day mortality
of 7% in 110 patients undergoing TAVI after previous car-
diac surgery [2]. Walther and colleagues reported a 30 day
mortality of 12% in a series of 25 high risk patients under-
going TAVI due to symptomatic aortic valve stenosis after
previous cardiac surgical interventions [22].
Besides early mortality permanent neurologic deficit
remain a concern in high risk patients with a history of
previous cardiac surgery. Transcatheter based aortic valve
implantation as analyzed, via the transapical approach, for
the purpose of the current study may substantially reduceor even abandon this devastating complication as evidenced
in a 0% stroke rate in our series. In the open surgical group
a significantly higher rate of permanent postoperative
neurologic events were observed (13%; p = 0.04). Stor-
tecky and colleagues assessed in a recent publication the
perioperative clinical outcome of patients undergoing
Redo-AVR or Redo-TAVI in a retrospective comparative
study of two randomly selected, non matched subgroups
of 40 patients each [20]. In their series they demonstrated
a lower incidence of stroke in the Redo-TAVI group. How-
ever this difference didn’t reach statistical significance.
The reported incidence of stroke in their series was 3%
(n = 1). Such a low rate of permanent neurologic compli-
cations is in accordance with previously published data
reporting an incidence of stroke of 0 to 1% after Redo-
TAVI [2,7]. Similarly to our data Ducroq et al. explored
the early and mid-term outcome of 54 patients undergo-
ing TAVI after previous CABG reporting excelent results
with an early stroke rate of 0% [7]. The improvement of
Figure 1 Time to event curves for early survival (A), early freedom from permanent neurologic complications (B) and early freedom
from adverse events (C). Events were calculated with the use of Kaplan Meier methods. Redo-TAVI denotes transcatheter based aortic valve
implantation after previous cardiac surgery and Redo-AVR surgical aortic valve replacement after previous cardiac surgery.
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a perioperative risk of close to 0% certainly represents a
powerful advantage of this evolving approach.
In general, surgical trauma is reduced due to the less
invasive nature of TAVI as pictured by elimination of
the need for mediastinal reentry, extensive adhesiolysis,
and the abolishment of extracorporal circulation. Statis-
tically this reduced surgical trauma is reflected in lower
postoperative chest tube drainage and a lower transfu-
sion rate of allogenic blood products in the Redo-TAVI
group. Similar results were observed by Strotecky and
colleagues, with a reported significantly lower require-
ment of blood components per patients in the Redo-
TAVI group compared to Redo-AVR [20].
Due to steadily increasing patient age and life expect-
ancy we learned from previous studies that even in octo-
genarians not only early operative outcomes but also
mid-term and late follow up data are crucial to adequately
compare TAVI to classic AVR [16]. During late follow-up,both groups were similar with respect to mortality and
new onset of neurologic events. Evaluation of the actuarial
survival after a mean follow up of 4 ± 2 years reveals com-
parable results regarding survival rate between the two
groups (75% vs. 73%, p = 0.56). In contrast the incidence
of major cerebrovascular events at 4 year follow up was
higher in the Redo-AVR group (15% vs. 0%, p = 0.03). As a
major finding of our study, we identified the difference
regarding the incidence of major adverse events, including
death and major neurologic complications (25% vs. 43%,
p = 0.01).
Echocardiographic data at 4 years revealed similar
results with respect to left ventricular function, aortic
valve orifice area, and transvalvular gradients for both
groups. Thirteen Redo-TAVI patients (33%) demonstrated
mild to moderate paravalvular insufficiency, while no
patient in the Redo-AVR group showed any paravalvular
regurgitation (p = 0.001). The observed rate of paravalvu-
lar leakage is in accordance with previously published data
Figure 2 Time to event curves for late survival (A), late freedom from permanent neurologic events (B) and freedom from adverse
events (C). Events were calculated with the use of Kaplan Meier methods. Redo-TAVI denotes transcatheter based aortic valve implantation after
previous cardiac surgery and Redo-AVR surgical aortic valve replacement after previous cardiac surgery.
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trial investigator group showed that the presence of para-
valvular leakage was associated with increased late morta-
lity [6]. In our series we could not find such a correlation,
probably due to the small number of patients investigatedTable 4 Echocardiographic data at late follow-up in







No. % No. %
Left ventricular ejection fraction 56 ± 4 58 ± 2 0.65
Mean transvalvular gradient (mmHg) 9.8 ± 3 10.1 ± 2 0.71
Effective orifice area (cm2) 1.5 ± 0.7 1.4 ± 0.5 0.78
Paravalvular leaks
Grade I/II 13 33 0 0 0.001
Grade III/IV 0 0 0 0 >0.99in the current study [6]. Interestingly, in our series none
of the 7 patients (18%) in the Redo-TAVI group, who
underwent valve in a valve procedure revealed paravalvu-
lar leakage. This may be related to the additional safety
net of an existing aortic bioprosthesis, which prevents the
risk of annular rupture and allows a more aggressive valve
deployment. Another survival benefit of Redo-TAVI pa-
tients may be due to the presence of patent CABG-grafts
which precludes the risk of coronary obstruction following
valve implantation. Nonetheless efforts to reduce the rate
of paravalvular leakage following TAVI with specific treat-
ment options or device features in second generation
treatment valves are currently being evaluated [23-26].
The encouraging findings in patients undergoing trans-
catheter based aortic valve implantations in previous
series have facilitated the ongoing investigation of patients
with a lower risk profile in the PARTNER II trial. We are
convinced that future guidelines for the proper patient
selection for TAVI should not only consider patient age
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presence of previous cardiac surgical interventions.
Conclusions
In conclusion, our data support outcomes reported in
the literature following Redo-AVR to treat valvular aortic
stenosis in high-risk patients with history of previous
cardiac surgery. The encouraging results regarding early
and long-term outcomes following TAVI in patients with
previous cardiac surgery show, that this evolving
approach may be particularly beneficial in this patient
cohort.
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